ILMN vs. NBIX: Illumina vs. Neurocrine Biosciences Stock Comparison

Company Profile

Illumina (ILMN) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while NBIX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Neurocrine Biosciences (NBIX) is defensive at 0.29 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Illumina (ILMN) at 32.39% and Neurocrine Biosciences (NBIX) at 20.42% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Illumina (ILMN) at 19.72% and Neurocrine Biosciences (NBIX) at 18.98% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Illumina (ILMN) at 20.02% and Neurocrine Biosciences (NBIX) at 31.98% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Illumina (ILMN) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Illumina (ILMN) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Illumina (ILMN) at 36.68 and Neurocrine Biosciences (NBIX) at 24.43 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Illumina (ILMN) at 7.10 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Neurocrine Biosciences (NBIX) at 4.30 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

Valuation Metrics